
Martin Frenzel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10907269/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2â ^{~?} Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology, 2017, 35, 2875-2884.	1.6	1,105
2	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology, 2017, 35, 3638-3646.	1.6	1,099
3	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2. JAMA Oncology, 2020, 6, 116.	7.1	572
4	Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discovery, 2016, 6, 740-753.	9.4	565
5	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 5218-5224.	7.0	492
6	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2â^', Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of Clinical Oncology, 2020, 38, 3987-3998.	1.6	478
7	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer, 2019, 5, 5.	5.2	352
8	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. Npj Breast Cancer, 2018, 4, 41.	5.2	41
9	Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer—Reply. JAMA Oncology, 2020, 6, 1122.	7.1	10
10	Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2â^'metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1. Breast Cancer Research and Treatment, 2020, 184, 161-172.	2.5	3